var data={"title":"Recombinant human growth hormone (somatropin): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Recombinant human growth hormone (somatropin): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6977?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=recombinant-human-growth-hormone-somatropin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Recombinant human growth hormone (somatropin): Patient drug information&quot;</a> and <a href=\"topic.htm?path=recombinant-human-growth-hormone-somatropin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Recombinant human growth hormone (somatropin): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222357\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Genotropin;</li>\n      <li>Genotropin MiniQuick;</li>\n      <li>Humatrope;</li>\n      <li>Norditropin FlexPro;</li>\n      <li>Norditropin NordiFlex Pen [DSC];</li>\n      <li>Nutropin AQ NuSpin 10;</li>\n      <li>Nutropin AQ NuSpin 20;</li>\n      <li>Nutropin AQ NuSpin 5;</li>\n      <li>Nutropin AQ Pen [DSC];</li>\n      <li>Omnitrope;</li>\n      <li>Saizen;</li>\n      <li>Saizen Click.Easy;</li>\n      <li>Saizenprep;</li>\n      <li>Serostim;</li>\n      <li>Tev-Tropin [DSC];</li>\n      <li>Zomacton;</li>\n      <li>Zorbtive</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222358\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Genotropin GoQuick;</li>\n      <li>Genotropin MiniQuick;</li>\n      <li>Humatrope;</li>\n      <li>Norditropin Nordiflex;</li>\n      <li>Norditropin Simplexx;</li>\n      <li>Nutropin AQ NuSpin;</li>\n      <li>Nutropin AQ Pen;</li>\n      <li>Omnitrope;</li>\n      <li>Saizen;</li>\n      <li>Serostim</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222378\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Growth Hormone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222360\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Nutropin (lyophilized powder) has been discontinued in the US for more than 1 year.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Growth hormone deficiency:</b> Adjust dose based on individual requirements: To minimize adverse events in older or overweight patients, reduced dosages may be necessary. During therapy, dosage should be decreased if required by the occurrence of side effects or excessive IGF-I levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Weight-based dosing:</b></i> <b>Note:</b> Obese patients are more likely to experience adverse effects when treated with a weight-based regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Norditropin:</i> SubQ: Initial dose &le;0.004 mg/kg/day; after ~6 weeks, may increase up to 0.016 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Nutropin, Nutropin AQ:</i> SubQ: &le;0.006 mg/kg/day; dose may be increased up to a maximum of 0.025 mg/kg/day in patients &le;35 years, or up to a maximum of 0.0125 mg/kg/day in patients &gt;35 years</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Humatrope:</i> SubQ: &le;0.006 mg/kg/day; dose may be increased up to a maximum of 0.0125 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Genotropin, Omnitrope:</i> SubQ: Weekly dosage: &le;0.04 mg/kg divided into equal doses 6 to 7 days per week; dose may be increased at 4- to 8-week intervals to a maximum of 0.08 mg/kg/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Saizen:</i> SubQ: &le;0.005 mg/kg/day; dose may be increased to &le;0.01 mg/kg/day after 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Zomacton:</i> SubQ: 0.006 mg/kg/day; dose may be increased up to a maximum of 0.0125 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Non-weight-based dosing:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer labeling:</i> SubQ: Initial: ~0.2 mg/day (range: 0.15 to 0.3 mg/day); may increase every 1 to 2 months by 0.1 to 0.2 mg/day based on response and/or serum IGF-I levels.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternative recommendations (off-label; </i>AACE [Cook 2009]): SubQ: Initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;30 years: 0.4 to 0.5 mg/day (higher doses may be needed if transitioning from pediatric treatment)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">30 to 60 years: 0.2 to 0.3 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lower initial doses (0.1 to 0.2 mg/day) may be needed in patients with diabetes or glucose intolerance. Adjust dose by 0.1 to 0.2 mg/day in 1- to 2-month intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment with estrogen supplementation:</i> Larger doses of somatropin may be needed for women taking oral estrogen replacement products; dosing not affected by topical products</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-associated adipose redistribution syndrome (HARS) (off-label use):</b> Serostim: SubQ: Induction: 4 mg once daily at bedtime for 12 weeks; Maintenance: 2 mg or 4 mg every other day at bedtime for 12 to 24 weeks. <b>Note:</b> Every-other-day dosing during induction has also been studied. Although a greater response was seen with daily dosing, it was associated with an increased incidence of adverse events (Grunfeld 2007; Kotler 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-associated wasting, cachexia: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Serostim:</i> SubQ: Initial: 0.1 mg/kg once daily at bedtime (maximum: 6 mg/day); patients at risk for side effects (eg, glucose intolerance) may be started at 0.1 mg/kg every other day. Adjust dose (ie, reduce the total daily dose or the number of doses per week) if needed to manage side effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Daily dose based on body weight:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;35 kg: 0.1 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">35 to 45 kg: 4 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">45 to 55 kg: 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;55 kg: 6 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Short-bowel syndrome:</b> <i>Zorbtive:</i> SubQ: 0.1 mg/kg once daily for 4 weeks (maximum: 8 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Fluid retention (moderate) or arthralgias:</i> Treat symptomatically or reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Severe toxicity:</i> Discontinue therapy for up to 5 days; when symptoms resolve, restart at 50% of dose. If severe toxicity recurs or does not disappear within 5 days after discontinuation, permanently discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222371\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=recombinant-human-growth-hormone-somatropin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Recombinant human growth hormone (somatropin): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Nutropin (lyophilized powder) has been discontinued in the US for more than 1 year.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Growth hormone deficiency:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Genotropin, Omnitrope:</i> SubQ: Weekly dosage: 0.16 to 0.24 mg/kg divided into equal doses 6 to 7 days per week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Humatrope:</i> SubQ: Weekly dosage: 0.18 to 0.3 mg/kg divided into equal doses 6 to 7 days per week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Norditropin: </i>SubQ: 0.024 to 0.034 mg/kg/day, 6 to 7 days per week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nutropin, Nutropin AQ:</i> SubQ: Weekly dosage: 0.3 mg/kg divided into equal daily doses; pubertal patients: &le;0.7 mg/kg divided into equal daily doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Saizen:</i> SubQ: Weekly dosage: 0.18 mg/kg divided into equal daily doses <b>or</b> as 0.06 mg/kg/dose administered 3 days per week <b>or</b> as 0.03 mg/kg/dose administered 6 days per week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tev-Tropin: </i>SubQ: &le;0.1 mg/kg/dose 3 days per week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Zomacton:</i> SubQ: Weekly dosage: 0.18 to 0.3 mg/kg/week (0.026 to 0.043 mg/kg/day) divided into equal doses and administered either 3, 6, or 7 days per week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Therapy should be discontinued when patient has reached satisfactory height, when epiphyses have fused, or when the patient ceases to respond. Some guidelines recommend discontinuing therapy when growth velocity is &lt;2 to 2.5 cm/year (Grimberg 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Growth failure secondary to chronic kidney disease (CKD):</b> <i>Nutropin, Nutropin AQ:</i> SubQ: Weekly dosage: &le;0.35 mg/kg divided into daily injections; continue until the time of renal transplantation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dosage recommendations in patients treated for CKD who require dialysis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hemodialysis:</i> Administer dose at night prior to bedtime or at least 3 to 4 hours after hemodialysis to prevent hematoma formation from heparin.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CCPD:</i> Administer dose in the morning following dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CAPD:</i> Administer dose in the evening at the time of overnight exchange.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Turner syndrome:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Genotropin, Omnitrope:</i> SubQ: Weekly dosage: 0.33 mg/kg divided into equal doses 6 to 7 days per week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Humatrope:</i> SubQ: Weekly dosage: &le;0.375 mg/kg divided into equal doses 6 to 7 days per week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Norditropin:</i> SubQ: &le;0.067 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nutropin, Nutropin AQ:</i> SubQ: Weekly dosage: &le;0.375 mg/kg divided into equal doses 3 to 7 days per week.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prader-Willi syndrome:</b> <i>Genotropin, Omnitrope:</i> SubQ: Weekly dosage: 0.24 mg/kg divided into equal doses 6 to 7 days per week</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Small for gestational age:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Genotropin, Omnitrope:</i> SubQ: Weekly dosage: &le;0.48 mg/kg divided into equal doses 6 to 7 days per week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Humatrope:</i> SubQ: Weekly dosage: &le;0.47 mg/kg divided into equal doses 6 to 7 days per week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Norditropin:</i> SubQ: &le;0.067 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing (small for gestational age):</i> In older/pubertal children or children with very short stature (ie, height SDS &lt;&ndash;3), consider initiating therapy at higher doses (eg, 0.067 mg/kg/day [0.48 mg/kg/week]) and then consider reducing the dose (eg, gradually towards 0.033 mg/kg/day [0.24 mg/kg/week]) if substantial catch-up growth observed during the first few years of therapy. In younger children (~&lt;4 years) with less severe short stature (ie, baseline height SDS values between -2 and -3), consider initiating therapy with lower doses (eg, 0.033 mg/kg/day [0.24 mg/kg/week]) and then titrating the dose upwards as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Idiopathic short stature:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Genotropin, Omnitrope:</i> SubQ: Weekly dosage: &le;0.47 mg/kg divided into equal doses 6 to 7 days per week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Humatrope:</i> SubQ: Weekly dosage: &le;0.37 mg/kg divided into equal doses 6 to 7 days per week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nutropin, Nutropin AQ:</i> SubQ: Weekly dosage: &le;0.3 mg/kg divided into equal daily doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Short stature associated with Noonan syndrome:</b> <i>Norditropin:</i> SubQ: &le;0.066 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>SHOX deficiency:</b> <i>Humatrope:</i> SubQ: Weekly dosage: 0.35 mg/kg divided into equal doses 6 to 7 days per week</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV patients with wasting or cachexia (off-label use):</b> <i>Serostim:</i> SubQ: Limited data; doses of 0.04 mg/kg/day were reported in five children, 6 to 17 years of age; doses of 0.07 mg/kg/day were reported in six children, 8 to 14 years of age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222361\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Consider a lower starting dose and smaller dose increments.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patients &gt;60 years: Initial dose: SubQ: 0.1 to 0.2 mg/day. Longer timer time intervals between dose titration and smaller dose changes may be needed in older patients (AACE [Cook 2009]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222362\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; decreased clearance in patients with chronic renal failure and end-stage renal disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222363\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; reduced clearance in patients with severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222338\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Norditropin FlexPro: 5 mg/1.5 mL (1.5 mL); 10 mg/1.5 mL (1.5 mL); 15 mg/1.5 mL (1.5 mL); 30 mg/3 mL (3 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Norditropin NordiFlex Pen: 30 mg/3 mL (3 mL [DSC]) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nutropin AQ NuSpin 5: 5 mg/2 mL (2 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nutropin AQ NuSpin 10: 10 mg/2 mL (2 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nutropin AQ NuSpin 20: 20 mg/2 mL (2 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nutropin AQ Pen: 10 mg/2 mL (2 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nutropin AQ Pen: 20 mg/2 mL (2 mL [DSC]) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omnitrope: 5 mg/1.5 mL (1.5 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omnitrope: 10 mg/1.5 mL (1.5 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Humatrope: 5 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Humatrope: 6 mg (1 ea); 12 mg (1 ea); 24 mg (1 ea) [contains glycerin, metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Saizen: 5 mg (1 ea); 8.8 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Saizen Click.Easy: 8.8 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Saizenprep: 8.8 mg (1 ea) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genotropin: 5 mg (1 ea); 12 mg (1 ea) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omnitrope: 5.8 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Serostim: 4 mg (1 ea); 5 mg (1 ea); 6 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tev-Tropin: 5 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zomacton: 5 mg (1 ea) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zomacton: 10 mg (1 ea) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zorbtive: 8.8 mg (1 ea) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genotropin MiniQuick: 0.2 mg (1 ea); 0.4 mg (1 ea); 0.6 mg (1 ea); 0.8 mg (1 ea); 1 mg (1 ea); 1.2 mg (1 ea); 1.4 mg (1 ea); 1.6 mg (1 ea); 1.8 mg (1 ea); 2 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222323\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27662100\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Nutropin (lyophilized powder) has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222340\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Do not shake. Administer SubQ; do not inject IV. Rotate administration sites (back of upper arm, abdomen, buttock, or thigh) to avoid tissue atrophy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222339\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Growth failure (pediatric patients):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of growth failure due to inadequate endogenous growth hormone secretion (Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Tev-Tropin, Zomacton).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of short stature associated with Turner syndrome (Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of Prader-Willi syndrome (Genotropin, Omnitrope).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of growth failure associated with chronic kidney disease up until the time of renal transplantation (Nutropin, Nutropin AQ).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of growth failure in children born small for gestational age who fail to manifest catch-up growth by 2 years of age (Genotropin, Omnitrope) or by 2 to 4 years of age (Humatrope, Norditropin)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of idiopathic short stature (nongrowth hormone-deficient short stature), defined by height standard deviation score (SDS) &le;-2.25 and growth rate not likely to attain adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom other causes associated with short stature have been excluded (Genotropin, Humatrope, Nutropin, Nutropin AQ, Omnitrope).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of short stature or growth failure associated with short stature homeobox gene (SHOX) deficiency (Humatrope).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of short stature associated with Noonan syndrome (Norditropin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Growth hormone deficiency (adults): </b>Replacement of endogenous growth hormone in adults with growth hormone deficiency who meet either of the following criteria (Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult-onset: Patients who have adult growth hormone deficiency whether alone or with multiple hormone deficiencies (hypopituitarism) as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Childhood-onset: Patients who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes, confirmed as an adult before replacement therapy is initiated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV-associated wasting, cachexia:</b> Treatment of HIV patients with wasting or cachexia (Serostim).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Short bowel syndrome:</b> Treatment of short-bowel syndrome in patients receiving specialized nutritional support (Zorbtive).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744908\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>HIV-associated adipose redistribution syndrome (HARS) (Serostim); Pediatric HIV patients with wasting/cachexia (Serostim)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222386\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Humatrope may be confused with homatropine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Somatrem may be confused with somatropin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Somatropin may be confused with homatropine, sumatriptan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Growth hormone is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older except as hormone replacement following pituitary gland removal due to its minimal impact on body composition and its association with causing edema, arthralgia, carpal tunnel syndrome, gynecomastia, and impaired fasting glucose (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222330\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (&le;69%), facial edema (&le;50%), edema (adults: &le;41%; children: &le;3%), lower extremity edema (adults: &le;15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (&le;19%), hypoesthesia (&le;15%), headache (adults: &le;18%; children: &le;7%), paresthesia (&le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypothyroidism (children: &le;16%; adults: &le;5%), elevated glycosylated hemoglobin (children: &le;14%), eosinophilia (children: &le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;13%), flatulence (&le;25%), abdominal pain (&le;25%), vomiting (&le;19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (children: &le;24%; binding capacity &ge;0.02 mg/mL: 2%; binding capacity &gt;2 mg/mL: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (adults: &le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (&le;31%), injection site reaction (&le;19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&le;44%), arthropathy (adults: &le;27%; children: 11%), myalgia (&le;30%), scoliosis (children: &le;19%; exacerbation or new), limb pain (4% to 19%), swelling of extremities (18%), ostealgia (adults: &le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otitis media (children: &le;16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (&le;16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (adults: &le;5%), hypertension (&le;8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (6% to 9%), nipple pain (&le;6%), depression (adults: &le;5%), insomnia (adults: &le;5%), carpal tunnel syndrome (1% to &lt;5%), sleep apnea (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (&le;8%), nevus (&le;2%; including progression and melanocytic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Impaired glucose tolerance (10%), hyperglycemia (1% to 9%), hyperlipidemia (children: &le;8%), gynecomastia (&le;6%), dependent edema (adults: &le;5%), diabetes mellitus (&le;5%; includes exacerbation and new-onset), hypertriglyceridemia (&le;5%), fluid retention (3% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Breast hypertrophy (&le;6%), breast neoplasm (&le;6%), breast swelling (&le;6%), breast tenderness (&le;6%), mastalgia (&le;6%), urinary tract infection (children: &le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hematoma (children: &le;9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (children: &le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Stiffness (adults: &le;8%; includes extremities and musculoskeletal), joint stiffness (4% to 8%), joint swelling (5% to 6%), leg pain (children: &le;5%), hip pain (children: &le;3%), tonsillitis (children: &le;3%), abnormal bone growth (children: &le;2%; including disproportional growth of lower jaw)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Periorbital edema (1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otitis (children: &le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (9%), flu-like symptoms (&le;8%), sinusitis (children: &le;3%), dyspnea (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Aggressive behavior (children), seizure (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (children), exacerbation of psoriasis (children), rash at injection site (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Disturbance in fluid balance (children), glycosuria (adults), hypoglycemia (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastroenteritis (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Hematuria (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Meningioma (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Bleeding at injection site (children), burning sensation at injection site (children), erythema at injection site (children), fibrosis at injection site (children), inflammation at injection site (children), injection site nodule (children), injection site numbness (children), local skin hyperpigmentation (children; injection site), swelling at injection site (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Lipoatrophy (children), musculoskeletal disease (discomfort), weakness (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngitis (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, arthritis, avascular necrosis of femoral head (Legg-Calve-Perthes disease), bone fracture, cardiac disease, CNS neoplasm (children), diabetic coma, diabetic ketoacidosis, diabetic retinopathy, hypersensitivity reaction, illness (acute critical), intracranial hypertension (includes benign intracranial hypertension in children), leukemia, malignant neoplasm (includes new or recurrence or intracranial tumor), neoplasm (children; benign, new or recurring), nerve compression, pancreatitis, papilledema, precocious puberty, slipped capital femoral epiphysis, visual disturbance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222343\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to somatropin or any component of the formulation; growth promotion in pediatric patients with closed epiphyses; acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure; active malignancy; active proliferative or severe nonproliferative diabetic retinopathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional product-specific contraindications:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment (Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients with Prader-Willi syndrome who have a history of upper airway obstruction or sleep apnea (Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Zomacton)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222327\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention: Fluid retention may occur in adults; manifestations of fluid retention (eg, edema, arthralgia, myalgia, nerve compression syndromes [including carpal tunnel syndrome]/paresthesias) are generally transient and dose dependent. If symptoms of carpal tunnel syndrome do not resolve by decreasing the dose or frequency of somatropin, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glucose tolerance: Somatropin may decrease insulin sensitivity. Previously undiagnosed impaired glucose tolerance and overt diabetes mellitus may be detected; new-onset type 2 diabetes mellitus, and exacerbation of preexisting diabetes mellitus may occur. Diabetic ketoacidosis and diabetic coma have been reported in some patients. Discontinuing somatropin may improve glucose tolerance in some patients. Adjustment of antidiabetic medications may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Serious systemic hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intracranial hypertension: Intracranial hypertension with headache, nausea, papilledema, visual changes, and/or vomiting has been reported; symptoms usually occur within the first 8 weeks of therapy and signs and symptoms of intracranial hypertension may rapidly resolve after discontinuation or reduction of dose. Funduscopic examination prior to initiation of therapy and periodically thereafter is recommended. Treatment should be discontinued in patients who develop papilledema; resuming treatment at a lower dose may be considered once IH-associated signs and symptoms have resolved. Patients with Turner syndrome, chronic renal impairment and Prader-Willi syndrome may be at increased risk for intracranial hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lipoatrophy: Lipoatrophy has been reported at injection sites when used at the same site for a prolonged period. Ensure proper injection technique and rotate injection sites.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neoplasm: Any preexisting malignancy should be inactive and treatment complete prior to initiating therapy; discontinue therapy with evidence of recurrence or progression. Monitor patients with preexisting tumors or growth hormone deficiency secondary to an intracranial lesion for recurrence or progression of underlying disease. An increased risk of second neoplasm has been reported in childhood cancer survivors treated with somatropin; the most common second neoplasms were meningiomas in patients treated with radiation to the head for their first neoplasm. Patients with HIV and pediatric patients with short stature (genetic cause) have increased baseline risk of developing malignancies; consider risk/benefits prior to initiation of therapy and monitor these patients carefully. Monitor all patients for any malignant transformation of skin lesions. Rule out pituitary tumor (or other brain tumors) prior to initiation of treatment because growth hormone deficiency may be an early sign of the presence of these tumors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Has been rarely reported; incidence in children (especially girls) with Turner syndrome may be greater than adults. Consider pancreatitis diagnosis if abdominal pain occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Slipped capital femoral epiphyses: Patients with endocrine disorders (including growth hormone deficiency and Turner syndrome) or in patients undergoing rapid growth may develop slipped capital femoral epiphyses more frequently; evaluate any child with new onset of a limp or with complaints of hip or knee pain.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute critical illness: Initiation of somatropin is contraindicated with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure; mortality may be increased. Discontinuation of therapy may be necessary in patients with an acute critical illness.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Childhood-onset adult growth hormone deficiency: Patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin for growth hormone deficiency in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic kidney disease: Periodically monitor children with growth failure secondary to chronic kidney disease (CKD) for evidence of progression of renal osteodystrophy. Slipped capital femoral epiphysis or avascular necrosis of the femoral head may be seen in children with advanced renal osteodystrophy. Obtain x-rays of the hip prior to initiating somatropin in CKD patients; be alert to the development of a limp or complaints of hip or knee pain.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoadrenalism: Patients who have or are at risk for pituitary hormone deficiency(s) may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism with somatropin therapy; patients with previously diagnosed hypoadrenalism may require increased dosages of glucocorticoids due to the effects of somatropin. Excessive glucocorticoid therapy may inhibit the growth-promoting effects of somatropin in children; monitor and adjust glucocorticoids carefully.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: Patients who have or are at risk for pituitary hormone deficiency(s) may be at risk for reduced thyroid function (central hypothyroidism). Untreated/undiagnosed hypothyroidism may decrease response to therapy, particularly the growth response in children. Monitor thyroid function periodically and initiate/adjust thyroid replacement therapy as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Noonan syndrome: Safety has not been established for the treatment of Noonan syndrome in children with significant cardiac disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prader-Willi syndrome: Fatalities have been reported in pediatric patients with Prader-Willi syndrome following the use of growth hormone. The reported fatalities occurred in patients with one or more risk factors, including severe obesity, history of upper airway obstruction or sleep apnea, respiratory impairment, or unidentified respiratory infection; male patients may be at greater risk. Monitor for sleep apnea, upper airway obstruction, and respiratory infections prior to initiation of therapy and periodically thereafter. Treatment interruption is recommended in patients who show signs of upper airway obstruction, including the onset of, or increased, snoring and/or new-onset sleep apnea. All patients with Prader-Willi syndrome should have effective weight control. Unless patients with Prader-Willi syndrome <b>also</b> have a diagnosis of growth hormone deficiency, use is not indicated for the long-term treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Scoliosis: Progression of scoliosis may occur in children experiencing rapid growth; monitor for worsening of scoliosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Turner syndrome: Patients with Turner syndrome are at increased risk for otitis media and other ear/hearing disorders, autoimmune thyroid disease, primary hypothyroidism, and cardiovascular disorders (eg, hypertension, aortic aneurysm/dissection, stroke). Monitor patients with Turner syndrome for these conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Elderly patients may be more sensitive to the actions of somatropin; consider lower starting doses and smaller dose increments.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV patients: Patients with HIV infection should be maintained on antiretroviral therapy to prevent the potential increase in viral replication.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Failure to increase growth rate, particularly during the first year of therapy, indicates need for close assessment of compliance and evaluation for other causes of growth failure, such as hypothyroidism, undernutrition, advanced bone age, and antibodies to recombinant human GH.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal transplant recipients: No studies have been completed evaluating Nutropin or Nutropin AQ in patients with renal transplant. Use is not indicated in patients with functioning renal allografts.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Diluent may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; M-cresol: Some products may contain m-cresol as a preservative.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple-dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300073\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222332\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9456&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cortisone: Somatropin may diminish the therapeutic effect of Cortisone. Growth hormone may reduce the conversion of cortisone to the active cortisol metabolite. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women. Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).<b> Exceptions: </b>Ethinyl Estradiol; Mestranol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Growth Hormone Products may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PredniSONE: Somatropin may diminish the therapeutic effect of PredniSONE. Growth hormone may reduce the conversion of prednisone to the active prednisolone metabolite. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Somatropin may diminish the therapeutic effect of Thyroid Products. <b> Exceptions: </b>Liothyronine.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222334\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B/C (depending upon manufacturer) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3984740\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies, however, reproduction studies have not been conducted with all agents. During normal pregnancy, maternal production of endogenous growth hormone decreases as placental growth hormone production increases. Data with somatropin use during pregnancy is limited (Vila 2015; Yoshizawa 2017) and recommendations related to use in pregnant women cannot be made (AACE [Cook 2009]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20688388\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if somatropin is present in breast milk. Endogenous growth hormone is involved in the establishment of lactogenesis and use of recombinant growth hormone has been evaluated as a galactogogue. However data related to this use is insufficient; nonpharmacologic measures should be considered prior to the use of medications (ABM 2011). Adverse events have not been reported in breastfed infants following maternal use (limited data). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222336\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of growth hormone deficiency (children):</b> Growth response; funduscopic exam prior to treatment; progression of scoliosis in patients with a history of scoliosis; clinical evidence of slipped capital femoral epiphysis, such as a limp or hip or knee pain; thyroid function; glucose in patients with risk factors for glucose intolerance; progression or recurrence of tumor in patients treated for growth deficiency secondary to a tumor or tumor development in at risk patients; progression of pre-existing nevi. In addition, guidelines recommend a physical exam at every visit; monitoring serum IGF-I; adrenal and thyroid function in patients with growth hormone deficiency due to multiple pituitary hormone deficiencies; funduscopic exam if symptoms of intracranial hypertension occur (Grimberg [PES 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic kidney disease: Progression of renal osteodystrophy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Idiopathic short stature: height, weight, pubertal development and adverse events every 3 to 6 months (Cohen 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prader-Willi syndrome: Signs of upper airway obstruction (including onset of or increased snoring), sleep apnea, respiratory infections; effective weight control.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Turner syndrome: Ear disorders including otitis media; cardiovascular disorders (eg, stroke, aortic aneurysm/dissection, hypertension).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Noonan syndrome: Prior to use, verify short stature syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of growth hormone deficiency (adults): </b>Monitor clinical response, serum IGF-I, and side effects every 1 to 2 months during dose titration. Once at maintenance dose, monitor serum IGF-I, fasting glucose, hemoglobin A1c, BMI, waist circumference/waist to hip ratio, thyroid function (free T<sub>4</sub>), adrenal function, lipid profile, blood pressure, clinical response and side effects semiannually. BMD should be evaluated prior to therapy and DXA scan repeated every 1.5 to 3 years if initial bone scan is abnormal (AACE [Cook 2009]; ES [Molitch 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Short bowel syndrome: </b>Diet should be optimized prior to therapy and nutritional status monitored during treatment; colonoscopy prior to therapy (in patients with residual colon) especially if risk factors for colon cancer are present (Steiger 2006). In addition, monitor for progression of preexisting nevi; glucose in patients with risk factors for glucose intolerance; thyroid function prior to and 4 weeks after treatment initiation in patients with suspected or diagnosed hypopituitarism; funduscopic examination at initiation of therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222326\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Somatropin is a purified polypeptide hormones of recombinant DNA origin; somatropin contains the identical sequence of amino acids found in human growth hormone; human growth hormone assists growth of linear bone, skeletal muscle, and organs by stimulating chondrocyte proliferation and differentiation, lipolysis, protein synthesis, and hepatic glucose output; stimulates erythropoietin which increases red blood cell mass; exerts both insulin-like and diabetogenic effects; enhances the transmucosal transport of water, electrolytes, and nutrients across the gut</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222342\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Nutropin AQ: 50 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic and renal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: Nutropin AQ; Saizen; Serostim; Zorbtive: 70% to 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genotropin: SubQ: 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Humatrope: SubQ: 3.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Norditropin: SubQ: ~7 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nutropin, Nutropin AQ: SubQ: 2.1 &plusmn; 0.43 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Omnitrope: SubQ: 2.5 to 2.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Saizen: SubQ: ~2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serostim: SubQ: 4.28 &plusmn; 2.15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zomacton: SubQ: <b>~</b>2.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zorbtive: SubQ: 4 &plusmn; 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222345\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Norditropin FlexPro Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/1.5 mL (1.5 mL): $706.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/1.5 mL (1.5 mL): $1,413.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg/1.5 mL (1.5 mL): $2,120.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/3 mL (3 mL): $4,240.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nutropin AQ NuSpin 10 Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/2 mL (2 mL): $1,508.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nutropin AQ NuSpin 20 Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/2 mL (2 mL): $3,017.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nutropin AQ NuSpin 5 Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/2 mL (2 mL): $754.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Omnitrope Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/1.5 mL (1.5 mL): $714.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/1.5 mL (1.5 mL): $1,429.09</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Genotropin MiniQuick Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg (1): $31.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg (1): $63.51</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (1): $95.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8 mg (1): $127.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (1): $158.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.2 mg (1): $190.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.4 mg (1): $222.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.6 mg (1): $254.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.8 mg (1): $285.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (1): $317.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Genotropin Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $728.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg (1): $1,747.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Humatrope Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $736.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (1): $883.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg (1): $1,766.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">24 mg (1): $3,533.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Omnitrope Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5.8 mg (1): $367.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Saizen Click.Easy Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.8 mg (1): $1,134.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Saizen Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $709.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.8 mg (1): $1,134.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Saizenprep Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.8 mg (1): $1,134.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Serostim Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (1): $396.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $496.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (1): $595.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Zomacton Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $348.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $696.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Zorbtive Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.8 mg (1): $1,462.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222347\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Caretropin (PH);</li>\n      <li>Declage (KR);</li>\n      <li>Eutropin (BR, IN, KR, TH);</li>\n      <li>Genheal (PH, TH);</li>\n      <li>Genotonorm (BE, ES, FR, LU);</li>\n      <li>Genotonorm Miniquick (FR);</li>\n      <li>Genotropin (AE, AR, AT, AU, BB, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, EG, FI, GB, GR, GT, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JO, KR, KW, LB, LT, LY, MT, MX, NI, NL, NO, NZ, OM, PA, PE, PK, PL, PT, QA, RO, RU, SA, SE, SI, SK, SV, SY, TH, TR, UY, VE, YE);</li>\n      <li>Genotropin Miniquick (BB);</li>\n      <li>Growject BC (JP);</li>\n      <li>Growtropin II (VN);</li>\n      <li>Growtropin-Aq (CO);</li>\n      <li>Growtropin-II (KR);</li>\n      <li>Henotropin (UA);</li>\n      <li>HHT (EC);</li>\n      <li>Humatrope (AR, AT, AU, BF, BJ, BR, CI, CL, ES, ET, GB, GH, GM, GN, KE, LK, LR, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, PE, SC, SD, SL, SN, TN, TW, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Nordilet (JO, KR);</li>\n      <li>Norditropin (AE, AR, AT, BB, BE, BG, BH, BR, CL, CN, CO, CZ, DK, EG, FI, GB, GR, HR, HU, ID, IE, IT, JO, JP, KR, KW, LB, LU, MT, MY, NL, NO, PT, QA, RO, RU, SA, SE, TW, UA, VN);</li>\n      <li>Norditropin Nordilet (SG, TH);</li>\n      <li>Norditropin S (JP);</li>\n      <li>Norditropin Simplex (KR);</li>\n      <li>Norditropin Simplexx (DE, ES, IS, LT, SI, SK);</li>\n      <li>Novell-Eutropin (ID);</li>\n      <li>Nutropin AQ (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);</li>\n      <li>Nutropinaq (FR);</li>\n      <li>Omnitrop (UA);</li>\n      <li>Omnitrope (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, MT, NL, NO, NZ, PL, PT, RU, SE, SK, TR);</li>\n      <li>Saizen (AE, AR, AT, AU, BB, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DO, EC, EE, ES, FI, FR, GR, GT, HK, HN, HU, ID, IE, IL, IS, IT, JO, KR, KW, LB, MY, NI, NO, NZ, PA, PH, PT, QA, SA, SE, SG, SK, SV, TH, TR, TW, VN);</li>\n      <li>Sayzen (UA);</li>\n      <li>Scitropin (PH);</li>\n      <li>Scitropin A (AU, TH);</li>\n      <li>Scitropina (SG);</li>\n      <li>Somatonorm (HR);</li>\n      <li>Valtropin (AT, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);</li>\n      <li>Xerendig (MX);</li>\n      <li>Zoamcton (PE);</li>\n      <li>Zomacton (AR, AT, AU, BE, BG, CZ, DK, EE, FI, GR, HK, KR, LT, NL, NO, RO, SE, SG, SK, VN);</li>\n      <li>Zomakton (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #9: use of galactogogues in initiating or augmenting the rate of maternal milk secretion (First Revision January 2011). <i>Breastfeed Med</i>. 2011;6(1):41-49.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blum WF, Crowe BJ, Quigley CA, et al, &ldquo;Growth Hormone is Effective in Treatment of Short Stature Associated With SHOX Deficiency: Two-year Results of a Randomized, Controlled, Multi-Center Trial,&rdquo; <i>J Clin Endocrinol Metab</i>, 2007, 92(1):219-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/17047016/pubmed\" target=\"_blank\" id=\"17047016\">17047016</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href=\"http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html\" target=\"_blank\">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clayton PE, Cianfarani S, Czernichow P, et al, &ldquo;Consensus Statement: Management of the Child Born Small for Gestational Age Through to Adulthood: A Consensus Statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society,&rdquo; <i>J Clin Endrocrinol Metab</i>, 2007, 92(3):804-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/17200164/pubmed\" target=\"_blank\" id=\"17200164\">17200164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen P, Rogol AD, Deal CL, et al, &ldquo;Consensus Statement on the Diagnosis and Treatment of Children With Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop,&rdquo; <i>J Clin Endocrinol Metab</i>, 2008, 93(11):4210-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/18782877/pubmed\" target=\"_blank\" id=\"18782877\">18782877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cook DM, Ludlam WH, and Cook MB. &ldquo;Route of Estrogen Administration Helps to Determine Growth Hormone (GH) Replacement Dose in GH-Deficient Adults,&rdquo; <i>J Clin Endocrinol Metab</i>, 1999, 84(11):3956-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/10566634/pubmed\" target=\"_blank\" id=\"10566634\">10566634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML; American Association of Clinical Endocrinologists (AACE). American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. <i>Endocr Pract</i>. 2009;15(Suppl 2):S1-S29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/20228036/pubmed\" target=\"_blank\" id=\"20228036\">20228036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Genotropin (somatropin) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    GH Research Society, &ldquo;Consensus Guidelines for the Diagnosis and Treatment of Growth Hormone (GH) Deficiency in Childhood and Adolescence: Summary Statement of the GH Research Society,&rdquo; <i>J Clin Endocrinol Metab</i>, 2000, 85(11):3990-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/11095419/pubmed\" target=\"_blank\" id=\"11095419\">11095419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grimberg A, DiVall SA, Polychronakos C, et al; Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society (PES). Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. <i>Horm Res Paediatr</i>. 2016;86(6):361-397.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/27884013/pubmed\" target=\"_blank\" id=\"27884013\">27884013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17592343\"></a>Grunfeld C, Thompson M, Brown SJ, et al, &ldquo;Recombinant Human Growth Hormone to Treat HIV-Associated Adipose Redistribution Syndrome: 12-Week Induction and 24-Week Maintenance Therapy. Study 24380 Investigators Group,&rdquo; <i>J Acquir Immune Defic Syndr</i>, 2007, 45(3):286-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/17592343/pubmed\" target=\"_blank\" id=\"17592343\">17592343</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humatrope (somatropin) [prescribing information]. Indianapolis, IN: Lilly USA LLC; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15076238\"></a>Kotler DP, Muurahainen N, Grunfeld C, et al, &ldquo;Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients. Serostim in Adipose Redistribution Syndrome Study Group,&rdquo; <i>J Acquir Immune Defic Synd</i>, 2004, 35(3):239-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/15076238/pubmed\" target=\"_blank\" id=\"15076238\">15076238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society (ES). Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2011;96(6):1587-1609.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/21602453/pubmed\" target=\"_blank\" id=\"21602453\">21602453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Norditropin (somatropin) [prescribing information]. Plainsboro, NJ: Novo Nordisk; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nutropin (somatropin) [prescribing information]. South San Francisco, CA: Genentech; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nutropin AQ (somatropin) [prescribing information]. South San Francisco, CA: Genentech; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Omnitrope (somatropin) [prescribing information]. Princeton, NY: Sandoz; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saizen (somatropin) [prescribing information]. Rockland, MA: Serono Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Serostim (somatropin) [prescribing information]. Rockland, MA: Serono Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steiger E, DiBaise JK, Messing B, Matarese LE, Blethen S. Indications and recommendations for the use of recombinant human growth hormone in adult short bowel syndrome patients dependent on parenteral nutrition. <i>J Clin Gastroenterol</i>. 2006;40(Suppl 2):S99-S106.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/16770169/pubmed\" target=\"_blank\" id=\"16770169\">16770169</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tev-Tropin (somatropin) [prescribing information]. Horsham, PA: Teva Select Brands; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vila G, Akerblad AC, Mattsson AF, et al. Pregnancy outcomes in women with growth hormone deficiency. <i>Fertil Steril</i>. 2015;104(5):1210-1217.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/26256649/pubmed\" target=\"_blank\" id=\"26256649\">26256649</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshizawa M, Ieki Y, Takazakura E, et al. Successful pregnancies and deliveries in a patient with evolving hypopituitarism due to pituitary stalk transection syndrome: role of growth hormone replacement. <i>Intern Med</i>. 2017;56(5):527-530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/recombinant-human-growth-hormone-somatropin-drug-information/abstract-text/28250299/pubmed\" target=\"_blank\" id=\"28250299\">28250299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zomacton (somatropin) [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zorbtive (somatropin) [prescribing information]. Rockland, MA: Serono Inc; January 2018.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9456 Version 173.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F222357\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F222358\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F222378\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F222360\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F222371\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F222361\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F222362\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F222363\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F222338\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F222323\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F27662100\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F222340\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F222339\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744908\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F222386\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F222330\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F222343\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F222327\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300073\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F222332\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F222334\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3984740\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20688388\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F222336\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F222326\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F222342\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F222345\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F222347\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9456|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=recombinant-human-growth-hormone-somatropin-patient-drug-information\" class=\"drug drug_patient\">Recombinant human growth hormone (somatropin): Patient drug information</a></li><li><a href=\"topic.htm?path=recombinant-human-growth-hormone-somatropin-pediatric-drug-information\" class=\"drug drug_pediatric\">Recombinant human growth hormone (somatropin): Pediatric drug information</a></li></ul></div></div>","javascript":null}